Preclinical design and clinical translation of TB regimens (predictr) consortium
Active Cooperative Agreement Awarded Last action
- Award ID
- UM1AI179699
- Recipient
-
The Regents Of The University Of California. San Francisco UEI KMH5K9V7S518
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $49,359,999
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 52% complete
- Place of performance
- San Francisco, CA 94143, USA
Award details come from USAspending.gov.
Description
- Abstract
- The long duration and multidrug nature of tuberculosis (TB) treatment regimens pose obstacles to treatment completion for patients and providers, but also challenge research efforts to develop new and improved regi- mens. Without a validated early biomarker able to discriminate regimens with different curative potential, the field depends heavily on preclinical models. However, TB regimen development has been slow, often hindered and misled by poor preclinical-to-clinical translation. Animal models and pharmacometric modeling played key roles in developing groundbreaking novel regimens capable of shorting treatment durations for drug-susceptible and multidrug-resistant TB to 4 and 6 months, respectively. However, these tools are still not utilized to their full potential. Recent successes in TB drug discovery have produced additional clinical and preclinical drug candi- dates, which have revealed a new challenge: with many possible combinations, how to prioritize multidrug regi- mens to test in resource-intensive clinical trials? The most efficient "critical path" of preclinical experiments and modeling to follow to identifying and optimizing the best regimens for advancement to clinical trials remains uncertain. The proposed project will establish a comprehensive, collaborative, multidisciplinary consortium of scientific leaders, drug developers and other stakeholders to develop and pursue a preclinical and translational research agenda to identify novel regimens with the greatest potential for clinical success in adults and children with TB. The overarching hypothesis is that integration and analysis of specific preclinical and early clinical data using validated models and tools will enable data-driven clinical trial simulations that yield quantitative predictions of phase 2 and phase 3 trial endpoints useful to identify and rank regimens with the highest probability of clinical success in patients across the age and disease spectrum of pulmonary TB. Initial efforts will be aimed at refining and validating preclinical in vivo (balb/c and C3HEB/FEJ mouse) and in vitro models and translational tools by leveraging the largest data warehouse on TB drugs and regimens ever assembled, with data spanning from early preclinical stages to phase 3 clinical trials, for both back translation and forward prediction approaches to validation. The overall goal is to develop a fully data- and knowledge-driven approach to evaluate, prioritize and optimize novel drug regimens for clinical trials requiring only preclinical and early clinical trial data. In addition to endpoints based on bacterial burden and relapse (in mice), the RS ratio, a new portable biomarker of bacterial "health", will be evaluated as a complementary pharmacodynamic (PD) biomarker to increase efficiency and predictive accuracy of preclinical studies. The expected outcomes are novel methodologies of combining pre- clinical and early clinical data, a defined set of critical path experiments with predictive value, and a framework for model-informed decision-making based on quantitative predictions of clinical outcomes for emerging regi- mens prior to initiation of phase 2/3 trials. The predictions will be used to rank order candidate regimens for advancement to clinical trials.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $7,200,000 | |
| Amendment | $7,200,000 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $7,200,000 | |
| Amendment | $7,200,000 | |
| Amendment | $7,200,000 | |
| Amendment | $1,039,999 | |
| Amendment | $6,160,000 | |
| Original award | $6,160,000 |
Show all 11
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Universiteit Leiden | $100,000 | |
| Vanderbilt University Medical Center | $415,742 | |
| The Johns Hopkins University | $3,644,087 | |
| Universiteit Leiden | $100,000 | |
| The Global Alliance For TB Drug Development Inc. | $551,652 | |
| The Regents Of The University Of Colorado | $1,163,274 | |
| Colorado State University | $1,096,631 | |
| HMH Hospitals Corporation | $1,328,250 | |
| Trustees Of Tufts College | $1,237,500 | |
| The Rockefeller University | $254,250 | |
| Weill Medical College Of Cornell University | $2,288,250 |
Show all 11
Quick answers
Who received award UM1AI179699?
UM1AI179699 was awarded to The Regents Of The University Of California. San Francisco by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 26, 2024.
How much is award UM1AI179699 worth?
$49,359,999 has been obligated on UM1AI179699.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award